V outlook financial report | Chongqing Zhifei Biological Products Co.Ltd(300122) : lyophilized recombinant tuberculosis vaccine enters phase IIa clinical trial

Chongqing Zhifei Biological Products Co.Ltd(300122) (300122) announced on February 11 that the company recently learned that the freeze-dried recombinant tuberculosis vaccine (AEC / bc02) developed by Anhui zhifeilong Kema biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has completed phase I clinical research, and the preliminary results show that the vaccine has good safety and tolerance. At present, the preparation of phase IIa clinical trial of the product has been completed, the subject screening has been started, and the phase IIa clinical trial has been officially launched.